CXCR4 inhibitor plerixafor and G-CSF allow for an effective peripheral blood stem cell collection in patients who failed previous mobilization attempt

Translational Biomedicine

Volumn 1, Issue 1, 2010, Pages

  Basak, Grzegorz Wladyslaw ^a   Urbanowska, Elzbieta ^a   Witkowska, Magdalena ^a   Zdunczyk, Dorota ^a   Waszczuk Gajda, Anna ^a   Skwierawska, Kamila ^a   Drozd Sokolowska, Joanna ^a   Skibinska, Monika ^a   Glazer, Magdalena ^a   Madry, Krzysztof ^a   Torosian, Tigran ^a   Halaburda, Kazimierz ^a   Krol, Maria ^a   Serzysko, Karolina ^a   Rusicka, Patrycja ^a   Gontarewicz, Maciej ^a   Wiktor Jedrzejczak, Wieslaw ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PLACEBO; PLERIXAFOR; PREDNISONE; PROCARBAZINE; RITUXIMAB; SYNDECAN 1; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CD34 SELECTION; CELL COUNT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CRYOPRESERVATION; DRUG MEGADOSE; EVENING DOSAGE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LEUKAPHERESIS; LEUKOCYTOSIS; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPHIL COUNT; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STEM CELL MOBILIZATION; THROMBOCYTE COUNT;

EID: 78651255397     PISSN: None     EISSN: 21720479     Source Type: Journal    
DOI: 10.3823/407     Document Type: Article

References (15)

1. De Clercq E (2009) The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 77: 1655-1664.
2. Bensinger W, DiPersio JF, McCarty JM (2009) Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 43: 181-195.
3. Villalon L, Odriozola J, Larana JG, Zamora C, Perez de Oteyza J, et al. (2000) Autologous peripheral blood progenitor cell transplantation with <2 × 10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment. Hematol J 1: 374-381.
4. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, et al. (2005) The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106: 1867-1874.
5. Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, et al. (2009) Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 15: 1578-1586.
6. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, et al. (2009) Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 27: 4767-4773.
7. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, et al. (2008) AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 41: 331-338.
8. Lee HM, Wysoczynski M, Liu R, Shin DM, Kucia M, et al. (2010) Mobilization studies in complement-deficient mice reveal that optimal AMD3100 mobilization of hematopoietic stem cells depends on complement cascade activation by AMD3100-stimulated granulocytes. Leukemia 24: 573-582.
9. EMEA (2009) Mozobil. In: Agency EM, editor. EPARs for authorised medicinal products for human use.
10. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, et al. (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113: 5720-5726.
11. Stewart DA, Smith C, MacFarland R, Calandra G (2009) Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 15: 39-46.
12. Hubel K, Liles WC, Broxmeyer HE, Rodger E, Wood B, et al. (2004) Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist. Support Cancer Ther 1: 165-172.
13. Kroger N, Sonnenberg S, Cortes-Dericks L, Freiberger P, Mollnau H, et al. (2004) Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study. Transfusion 44: 104-110.
14. Burgstaler EA PA (2002) The negative effect of high peripheral white blood cell count on CD34+ cell recovery. Journal of Clinical Apheresis 17: 148.
15. Burgstaler EA PA, Winters JL (2003) Effects of high whole blood flow rates and high peripheral blood cell counts on CD34+ cell yield and cross-cellular contamination. Cytotherapy 5: 446.